Middle East and Africa Cardiac Resynchronization Therapy (CRT) Market Size, Share & Trends Analysis Report By Product (CRT-Defibrillator, CRT-Pacemaker), By End User (Hospitals, Cardiac Centers, Ambulatory Surgical Centers, Other End Users) and By Country (UAE, Turkey, Saudi Arabia, South Africa, Egypt, Nigeria, Rest of MEA) Forecasts, 2026-2034

Last Updated: September 21, 2026 | Author: Debashree Bora | Format:

Middle East and Africa Cardiac Resynchronization Therapy (CRT) Market Size

The Middle East and Africa Cardiac Resynchronization Therapy Market size was valued at USD 0.21 billion in 2025 and is projected to grow from USD 0.22 billion in 2026 to reach USD 0.33 billion by 2034, growing at a CAGR of 5.09% during the forecast period 2026–2034.

Cardiac resynchronization therapy (CRT) is a treatment that assists the heart in beating at the correct rate. It employs a pacemaker to restore the heartbeat's normal timing pattern. The CRT pacemaker coordinates the synchronization of the heart's upper (atria) and lower (ventricles) chambers. It also regulates the synchronization between the heart's left and right sides.

The market for cardiac resynchronization therapy (CRT) was estimated to be worth USD 5.85 billion in 2021. One of the major trends accelerating market expansion is the rapid advancement of technology. The market is expanding due to sedentary lifestyle adoption, an aging population, and increased cardiovascular disease prevalence.

Market Key Takeaways

Global Market Size & Growth

CRT-D dominates the market by Product.

Hospitals dominate the market by End-users.

South Africa dominates the market by Country.

Middle East and Africa Cardiac Resynchronization Therapy (CRT) Market Size

Download a Free Sample To learn more about this report.

Product Insights

The Middle East and Africa market is segmented by CRT-D and CRT-P. CRT-D dominated the market over the forecast period.

Middle East and Africa Cardiac Resynchronization Therapy (CRT) Market Size By Segments

Request Customizationto receive a tailored report.

End User Insights

The Middle East and Africa market is segmented by Hospitals, Cardiac Centre. Hospitals dominated the market over the forecast period.

Middle East and Africa Cardiac Resynchronization Therapy (CRT) Market Share By Segments

Speak to an Analystto discuss market opportunities.

Regional Analysis

The Middle East and Africa market is segmented by country into South Africa, Saudi Arabia, and UAE. South Africa dominates the country market and is expected to grow at a CAGR of 7.7% during the forecast period.

The MEA cardiac resynchronization therapy market is anticipated to grow due to key companies' initiatives and growing awareness of cardiovascular events in developing economies. Additionally, the presence of regional distributors and growing efforts to increase public awareness of heart health are anticipated to support market expansion in the upcoming years. According to a study done in Africa between 2011 and 2018, the region lacked widespread access to and utilization of cardiac arrhythmia services. CRT was discovered to be used in 12% or 52% of the responding African nations. Of the 23 countries that responded, 52% reported implanting CRT-P, while 45% reported implanting CRT-D. The cost was a substantial deterrent to using CRT-P and CRT-Ds in the area. The study identified key objectives for expanding cardiac arrhythmia services across Africa: increased economic investments, human resource training, and infrastructure improvements in the healthcare sector.

List of Key and Emerging Players in Middle East and Africa Cardiac Resynchronization Therapy (CRT) Market

Abbott

Boston Scientific Corporation

Medtronic

Lepu Medical Technology Co., Ltd.

Biotronik SE & Co. Kg

Microport Scientific Corporation

LivaNova PLC

Medico S.R.L.

Key Industry Developments

May 2026

BIOTRONIK entered a research and innovation partnership with Charité – Universitätsmedizin Berlin and the German Heart Center Foundation to advance digital cardiology, AI-enabled cardiac rhythm management, and connected implantable cardiac devices, including cardiac resynchronization therapy (CRT) systems. The collaboration supports future innovations adopted across global markets, including MEA.

April 2026

Boston Scientific received U.S. FDA approval for design updates to its RESONATE™ CRT-D family, including enhanced communication modules and hardware improvements. These upgrades strengthen the company's global CRT portfolio, including products marketed in the Middle East and Africa.

September 2025

BIOTRONIK launched the Amvia Sky HF-T QP CRT-P system in Canada, expanding its quadripolar cardiac resynchronization therapy portfolio with improved workflow features and patient-focused device capabilities. The launch reinforces BIOTRONIK's global CRT product offering for international markets, including MEA.

June 2025

Medtronic expanded educational and physician training initiatives for cardiac rhythm management technologies, including CRT implantation and remote monitoring solutions, through international clinical education programs supporting healthcare professionals in emerging markets, including the Middle East and Africa.

Report Scope

Segmentation

By Product 2

CRT-Defibrillator
CRT-Pacemaker

By End User 4

Hospitals
Cardiac Centers
Ambulatory Surgical Centers
Other End Users

Competitive Coverage Abbott · Boston Scientific Corporation · Medtronic · Lepu Medical Technology Co., Ltd. · Biotronik SE & Co. Kg

Research Deliverables Revenue Forecast, Competitive Landscape, Growth Factors, Environment & Regulatory Landscape and Trends

Customize This Report to Match Your Strategic Objectives

Frequently Asked Questions (FAQs)

The Middle East and Africa cardiac resynchronization therapy market witnessed significant growth in the past and is expected to grow at a CAGR of 5.09% during the forecast period (2026-2034).

Key verticals adopting the Middle East and Africa cardiac resynchronization therapy market include: Abbott, Boston Scientific Corporation, Medtronic, Lepu Medical Technology Co., Ltd., Biotronik SE & Co. Kg, Microport Scientific Corporation , LivaNova PLC, Medico S.R.L.

Rising awareness about cardiac resynchronization therapy (crt) is the key driver for the growth of the Middle East and Africa cardiac resynchronization therapy market.

Regulatory support is one of the upcoming key trends in the Middle East and Africa cardiac resynchronization therapy market.

About the Author

Debashree Bora

Healthcare Lead

Debashree Bora is a strategic healthcare research professional with nearly eight years of hands on experience in market intelligence, encompassing primary research, secondary research, market estimation, and consulting engagements. She specializes in pharmaceutical, biotechnology, medical devices, healthcare services, clinical trials, and healthcare outsourcing sectors, providing actionable insights on evolving industry trends, regulatory landscapes, and competitive dynamics.
Debashree’s research helps global clients evaluate market potential, identify growth opportunities, strengthen commercial strategies, and make informed business decisions.